Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Issue 18 (2nd November 2021)

• Record Type: Journal Article
• Authors: Fröbert, Ole; Götberg, Matthias; Erlinge, David; Akhtar, Zubair; Christiansen, Evald H.; MacIntyre, Chandini R.; Oldroyd, Keith G.; Motovska, Zuzana; Erglis, Andrejs; Moer, Rasmus; Hlinomaz, Ota; Jakobsen, Lars; Engstrøm, Thomas; Jensen, Lisette O.; Fallesen, Christian O.; Jensen, Svend E; Angerås, Oskar; Calais, Fredrik; Kåregren, Amra; Lauermann, Jörg; Mokhtari, Arash; Nilsson, Johan; Persson, Jonas; Stalby, Per; Islam, Abu K.M.M.; Rahman, Afzalur; Malik, Fazila; Choudhury, Sohel; Collier, Timothy; Pocock, Stuart J.; Pernow, John;
• Is Part Of: Circulation. Volume 144:Issue 18(2021)
• Publication Date: 2021-11-02
• Subjects: influenza vaccines -- myocardial infarction -- randomized controlled trial; Blood -- Circulation -- Periodicals; Cardiovascular system -- Periodicals; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; Blood Circulation; Cardiovascular System; Vascular Diseases; 616.1
• DOI: 10.1161/CIRCULATIONAHA.121.057042
• Languages: English
• ISSNs: 0009-7322

Abstract

Abstract : Background: Observational and small, randomized studies suggest that influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease. Methods: We conducted an investigator-initiated, randomized, double-blind trial to compare inactivated influenza vaccine with saline placebo administered shortly after myocardial infarction (MI; 99.7% of patients) or high-risk stable coronary heart disease (0.3%). The primary end point was the composite of all-cause death, MI, or stent thrombosis at 12 months. A hierarchical testing strategy was used for the key secondary end points: all-cause death, cardiovascular death, MI, and stent thrombosis. Results: Because of the COVID-19 pandemic, the data safety and monitoring board recommended to halt the trial before attaining the prespecified sample size. Between October 1, 2016, and March 1, 2020, 2571 participants were randomized at 30 centers across 8 countries. Participants assigned to influenza vaccine totaled 1290 and individuals assigned to placebo equaled 1281; of these, 2532 received the study treatment (1272 influenza vaccine and 1260 placebo) and were included in the modified intention to treat analysis. Over the 12-month follow-up, the primary outcome occurred in 67 participants (5.3%) assigned influenza vaccine and 91 participants (7.2%) assigned placebo (hazard ratio, 0.72 [95% CI, 0.52–0.99]; P =0.040). Rates of all-cause death were 2.9% and 4.9% (hazard ratio, 0.59 [95% CI, 0.39–0.89]; P =0.010), rates of cardiovascular death were 2.7% and 4.5%, (hazard ratio, 0.59 [95% CI, 0.39–0.90]; P =0.014), and rates of MI were 2.0% and 2.4% (hazard ratio, 0.86 [95% CI, 0.50–1.46]; P =0.57) in the influenza vaccine and placebo groups, respectively. Conclusions: Influenza vaccination early after an MI or in high-risk coronary heart disease resulted in a lower risk of a composite of all-cause death, MI, or stent thrombosis, and a lower risk of all-cause death and cardiovascular death, as well, at 12 months compared with placebo. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02831608. Abstract : Supplemental Digital Content is available in the text.